Report of Foreign Issuer (6-k)
February 28 2020 - 6:19AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 24, 2020
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 24 February 2020
– On 5 February 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation
No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052
of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to
DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.
Under the programme, initiated 5 February 2020,
Novo Nordisk will repurchase B shares for an amount up to DKK 2.9 billion in the period from 5 February 2020 to 4 May 2020.
Since the announcement
as of 14 February 2020, the following transactions have been made:
|
Number of
B shares
|
Average
purchase price
|
Transaction
value, DKK
|
Accumulated, last announcement
|
760,000
|
|
329,348,973
|
14 February 2020
|
110,000
|
436.04
|
47,964,919
|
17 February 2020
|
110,000
|
436.06
|
47,966,296
|
18 February 2020
|
110,000
|
441.46
|
48,560,293
|
19 February 2020
|
110,000
|
444.78
|
48,925,735
|
20 February 2020
|
110,000
|
443.48
|
48,782,847
|
21 February 2020
|
110,000
|
440.31
|
48,433,726
|
Accumulated under the programme
|
1,420,000
|
|
619,982,789
|
The details for each transaction made under the share repurchase
programme are published on novonordisk.com.
Transactions related to Novo Nordisk’s incentive programmes
have resulted in a net transfer from Novo Nordisk of 4,499 B shares in the period from 14 February 2020 to 21
Page 2 of 2
February 2020. The shares in these transactions
were not part of the Safe Harbour repurchase programme.
With the transactions
stated above, Novo Nordisk owns a total of 51,488,493 B shares of DKK 0.20, corresponding to 2.1% of the share capital, as treasury
shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up
to DKK 17 billion during a 12-month period beginning 5 February 2020. As of 21 February 2020, Novo Nordisk has since 5 February
2020 repurchased a total of 1,420,000 B shares at an average share price of DKK 436.61 per B share equal to a transaction value
of DKK 619,982,789.
Novo Nordisk
is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given
us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious
chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products
in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York
Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
Media:
|
|
|
Anne Margrethe Hauge
|
+45 4442 3450
|
amhg@novonordisk.com
|
Ken Inchausti (US)
|
+1 609 240 9429
|
kiau@novonordisk.com
|
|
|
|
Investors:
|
|
|
Peter Hugreffe Ankersen
|
+45 3075 9085
|
phak@novonordisk.com
|
Valdemar Borum Svarrer
|
+45 3079 0301
|
jvls@novonordisk.com
|
Ann Søndermølle Rendbæk
|
+45 3075 2253
|
arnd@novonordisk.com
|
Mark Joseph Root
|
+45 3079 4211
|
mjhr@novonordisk.com
|
Kristoffer Due Berg (US)
|
+1 609 235 2989
|
krdb@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 13 / 2020
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: February 24, 2020
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2023 to Jul 2024